HEALTH PROFESSIONAL · SOURCE READING

Metastatic HER2-Positive Breast Cancer

Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Metastatic Breast Cancer

Antibody therapy targeting the HER2 pathway has been used since the 1990s and has revolutionized the treatment of HER2-positive metastatic breast cancer. Several HER2-targeted agents (e.g., trastuzumab, pertuzumab, trastuzumab emtansine, lapatinib) have been approved for treatment of this disease.

Continue within this section

Monoclonal antibody therapy →Trastuzumab deruxtecan →Margetuximab →Tyrosine kinase inhibitor (TKI) therapy →mTOR inhibition →

Preserved source evidence · Not medical advice